Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

14:33
10/09/16
10/09
14:33
10/09/16
14:33

Merck reports interim KEYNOTE-052 data on Keytruda in urothelial cancer

Merck announced "positive" findings from the phase 2 KEYNOTE-052 study investigating the use of Keytruda in previously untreated patients with unresectable or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. Data presented at the ESMO 2016 Congress showed an overall response rate of 24 percent in the total study population, which included patients with and without PD-L1 expression. Findings presented at ESMO 2016 are from the planned interim analysis of the first 100 patients, which was intended to evaluate ORR and determine the PD-L1-high expression cut-point as examined by expression in tumor and immune cells. Forty-five percent of patients had an Eastern Cooperative Oncology Group Performance Status score of two, 30 percent had a PS score of one, and 24 percent had a PS score of zero. In the total study population, ORR was 24 percent with a complete response rate of six percent. Review of the outcomes based on PD-L1 expression showed that in patients with PD-L1 expression of less than one percent, ORR was 18 percent with a complete response rate of three percent; in patients with PD-L1 expression greater than or equal to one percent and less than 10 percent, ORR was 15 percent with no complete responses; and, in patients expressing PD-L1 at levels equal to or greater than 10 percent, ORR was 37 percent with a complete response rate of 13 percent. Among the 24 percent of patients in the total study population who were responding to treatment, the median duration of response had not been reached -- range 1.4+ to 9.8+ months -- with 83 percent of patients having responses of six months or longer. The safety profile of Keytruda was consistent with that observed in previously reported studies. Five patients discontinued due to a treatment-related adverse event; there were no treatment-related deaths.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

FSLR

First Solar

$48.86

0.32 (0.66%)

12:36
09/20/17
09/20
12:36
09/20/17
12:36
Hot Stocks
First Solar off lows after Deutsche's analysis of Friday's ITC ruling »

The shares remain down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$48.86

0.32 (0.66%)

12:35
09/20/17
09/20
12:35
09/20/17
12:35
Recommendations
First Solar analyst commentary  »

First Solar shares can…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:35
09/20/17
09/20
12:35
09/20/17
12:35
General news
FOMC forecast revisions »

FOMC forecast revisions…

AA

Alcoa

$47.30

1.1 (2.38%)

12:30
09/20/17
09/20
12:30
09/20/17
12:30
Options
All time high for Alcoa shares draws December premium buyers »

All time high for Alcoa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$38.99

0.29 (0.75%)

12:25
09/20/17
09/20
12:25
09/20/17
12:25
Periodicals
GM and striking workers union Unifor in informal talks, Automotive News says »

General Motors and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:21
09/20/17
09/20
12:21
09/20/17
12:21
Hot Stocks
Ackman says ADP CEO's stake lot more levered than Pershing's »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:20
09/20/17
09/20
12:20
09/20/17
12:20
Hot Stocks
Ackman says ADP stock options owned are 'very deep in the money' »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$16.71

-0.09 (-0.54%)

12:20
09/20/17
09/20
12:20
09/20/17
12:20
Options
Aggressive put buying in Canadian Solar »

Aggressive put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:18
09/20/17
09/20
12:18
09/20/17
12:18
Hot Stocks
ADP board has no shareholder orientation, Ackman says »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
09/20/17
09/20
12:17
09/20/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

, DLPH

Delphi

$100.97

0.07 (0.07%)

12:16
09/20/17
09/20
12:16
09/20/17
12:16
Periodicals
Delphi picks BlackBerry's QNX OS for self-driving platform, CNet reports »

Delphi (DLPH) has…

BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

DLPH

Delphi

$100.97

0.07 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

$NYE

NYSE Market Internals

12:16
09/20/17
09/20
12:16
09/20/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:15
09/20/17
09/20
12:15
09/20/17
12:15
Hot Stocks
Ackman says can work with ADP CEO after 'spoiled brat' comment »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
09/20/17
09/20
12:15
09/20/17
12:15
General news
FOMC balance sheet »

FOMC balance sheet: the…

ADP

ADP

$107.48

0.93 (0.87%)

12:14
09/20/17
09/20
12:14
09/20/17
12:14
Hot Stocks
Ackman says ADP margin opportunity closer to 1,200 basis points »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$309.39

5.98 (1.97%)

12:12
09/20/17
09/20
12:12
09/20/17
12:12
Hot Stocks
Ackman says Chipotle management doing 'all the right things' »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:11
09/20/17
09/20
12:11
09/20/17
12:11
Hot Stocks
ADP does not want shares held by Pershing supporters, Ackman says »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$921.81

6.81 (0.74%)

, GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

12:11
09/20/17
09/20
12:11
09/20/17
12:11
Periodicals
Google nears deal to buy assets from HTC, Bloomberg reports »

Google is nearing a deal…

GOOG

Alphabet

$921.81

6.81 (0.74%)

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

HMNY

Helios and Matheson

$5.70

2.22 (63.79%)

12:10
09/20/17
09/20
12:10
09/20/17
12:10
Periodicals
Helios and Matheson mentioned cautiously by TheStreetSweeper 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

, PAYX

Paychex

$58.07

-0.01 (-0.02%)

12:09
09/20/17
09/20
12:09
09/20/17
12:09
Hot Stocks
Ackman says 80% of ADP's issue is margins not at Paychex level »

Pershing Square's…

ADP

ADP

$107.48

0.93 (0.87%)

PAYX

Paychex

$58.07

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ADP

ADP

$107.48

0.93 (0.87%)

12:08
09/20/17
09/20
12:08
09/20/17
12:08
Hot Stocks
Ackman says ADP products are not easy enough to use »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:06
09/20/17
09/20
12:06
09/20/17
12:06
Hot Stocks
Ackman says ADP overstates total shareholder returns under CEO »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUXTY

Luxottica

$57.52

0.06 (0.10%)

, ESLOY

Essilor

$63.35

-0.06 (-0.09%)

12:06
09/20/17
09/20
12:06
09/20/17
12:06
Downgrade
Luxottica, Essilor rating change  »

Luxottica downgraded to…

LUXTY

Luxottica

$57.52

0.06 (0.10%)

ESLOY

Essilor

$63.35

-0.06 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSEC

Prospect Capital

$6.72

0.07 (1.05%)

12:05
09/20/17
09/20
12:05
09/20/17
12:05
Options
Prospect Capital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$107.48

0.93 (0.87%)

12:01
09/20/17
09/20
12:01
09/20/17
12:01
Hot Stocks
Bill Ackman says ADP has 'massively underperformed potential' »

Pershing Square's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.